DAS181 treatment of hematopoietic stem cell transplant patients with parainfluenza virus lung disease requiring mechanical ventilation. Issue 1 (3rd January 2014)

• Record Type: Journal Article
• Authors: Chalkias, S.; Mackenzie, M.R.; Gay, C.; Dooley, C.; Marty, F.M.; Moss, R.B.; Li, T.; Routh, R.L.; Walsh, S.R.; Tan, C.S.
• Is Part Of: Transplant infectious disease. Volume 16:Issue 1(2014)
• Page Start: 141
• Page End: 144
• Publication Date: 2014-01-03
• Subjects: Transplantation of organs, tissues, etc -- Complications -- Periodicals; Communicable diseases -- Periodicals; Infection -- Periodicals; 617.01
• DOI: 10.1111/tid.12177
• Languages: English
• ISSNs: 1398-2273

Abstract

<abstract abstract-type="main" id="tid12177-abs-0001"> <title>Abstract</title> <p>Parainfluenza infection is a cause of significant morbidity and mortality in allogeneic hematopoietic stem cell transplant (HSCT) patients. DAS181 is a novel antiviral agent with activity against influenza and parainfluenza. We report the first 2 cases, to our knowledge, of successful DAS181 use in ventilated HSCT patients with severe parainfluenza lung disease.</p> </abstract>